Octreotide Dosing for Pediatric GI Bleeding
For children with acute gastrointestinal bleeding, initiate octreotide with a 1 mcg/kg IV bolus (can repeat if ongoing bleeding), followed by continuous IV infusion at 1-2 mcg/kg/hour, continuing for 2-5 days after bleeding control.
Dosing Regimen
Initial Bolus
- 1 mcg/kg IV bolus at presentation 1, 2
- Can be repeated in the first hour if bleeding continues
- Some centers omit the bolus and proceed directly to infusion 1
Continuous Infusion
- Start at 1-2 mcg/kg/hour as continuous IV infusion 1, 2
- Mean starting dose in pediatric studies: 1.44 mcg/kg/hour 1
- Maximum doses used: up to 1.68 mcg/kg/hour 1
Duration
- Continue for 2-5 days after bleeding control 3
- This mirrors adult dosing recommendations where octreotide is the vasoactive drug of choice 4
Clinical Context
The evidence for pediatric octreotide dosing comes primarily from observational studies, as no pediatric-specific guidelines exist 5. The dosing extrapolates from adult variceal bleeding protocols while adjusting for weight-based calculations. In adults, the standard regimen is 50 mcg IV bolus followed by 50 mcg/hour continuous infusion 3, which translates to approximately 1 mcg/kg/hour for a 50 kg patient.
Efficacy Data
Pediatric studies demonstrate:
- 71% bleeding cessation rate during octreotide infusion in portal hypertension 2
- Reduced transfusion requirements from 23 mL/kg to 8 mL/kg (p<0.01) 6
- Rebleeding occurred in 29-52% of cases, though hemostasis was eventually achieved in all 1, 2
Administration Details
- Dilute in 50-200 mL normal saline or D5W 7
- Can infuse over 15-30 minutes or give as IV push over 3 minutes 7
- In emergency situations (e.g., massive hemorrhage), may give as rapid bolus 7
- Not compatible with TPN solutions 7
Important Caveats
When to Start
- Initiate as soon as variceal bleeding is suspected, preferably before endoscopy 4, 3
- Start simultaneously with antibiotic prophylaxis (ceftriaxone 50 mg/kg/day, max 1g daily) 3
When to Stop
- Discontinue if endoscopy reveals non-variceal source of bleeding 4
- The drug is specifically effective for portal hypertension-related bleeding; its role in non-variceal pediatric GI bleeding is less clear with only 50% response rates 2
Monitoring for Adverse Events
While generally safe in pediatric populations 1, 2, 5, monitor for:
- Hyperglycemia (most common, usually mild and reversible) 6, 5
- QT prolongation (rare but serious) 6
- Hypertension 6
- Growth hormone suppression with prolonged use 6
Dosing Adjustments
- If bleeding persists despite initial dosing, the infusion rate can be increased, though experience above 2 mcg/kg/hour is limited 1, 2
- In adult protocols, additional boluses can be given for ongoing bleeding 3; this approach is reasonable in pediatrics
Key Differences from Adult Dosing
Adult dosing uses fixed doses (50 mcg bolus, 50 mcg/hour infusion) 3, while pediatric dosing requires weight-based calculations (1 mcg/kg bolus, 1-2 mcg/kg/hour). This weight-based approach ensures appropriate dosing across the wide age and size range in pediatrics, from neonates to adolescents 8, 6.
The 2-5 day duration recommendation is consistent across both adult and pediatric populations, as this timeframe prevents early rebleeding after initial endoscopic hemostasis 4, 3.